ASCO Meeting 2019 Participation

Oral Abstract Session:
Friday, May 31
2:45 – 5:45 PM
Location: E450

Head and Neck Cancer
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Clinical Science Symposium:
Saturday, June 1
8:00 – 9:30 AM
Location: Hall D1

Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition
Authors: Jeffrey S. Weber, Hao Tang, Lauren Hippeli, Max Qian, Megan Wind-Rotolo, James M.G. Larkin, Jedd D. Wolchok, Mario Sznol, Caroline Robert, David Michael Woods, Andressa Sodre Laino, F. Stephen Hodi

Poster Session:
Saturday, June 1
8:00 – 11:00 AM
Location: Hall A

Developmental Immunotherapy and Tumor Immunobiology
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab
Authors: Michael E. Hurwitz, Daniel C. Cho, Arjun Vasant Balar, Brendan D. Curti, Arlene O. Siefker-Radtke, Mario Sznol, Harriet M. Kluger, Chantale Bernatchez, Christie Fanton, Ernesto Iacucci, Yi Liu, Tuan Nguyen, Willem Overwijk, Jonathan Zalevsky, Mary Ann Tagliaferri, Ute Hoch, Adi Diab
Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors

Authors: Jasgit C. Sachdev, Todd Michael Bauer, Sant P. Chawla, Shubham Pant, Amita Patnaik, Zev A. Wainberg, Sandeep P. Inamdar, Neyssa Marina, Stefanie Sun, Maike Schmidt, Hong Xiang, Patricia LoRusso

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072


A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy

Authors: Laura Quan Man Chow, Justin F. Gainor, Nehal J. Lakhani, Hyun Cheol Chung, Keun-Wook Lee, Jeeyun Lee, Patricia LoRusso, Yung-Jue Bang, F. Stephen Hodi, Philip Fanning, Yonggang Zhao, Feng Jin, Hong Wan, Jaume Pons, Sophia Randolph, Wells A. Messersmith

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy

Authors: Timothy A Yap, Kyriakos P. Papadopoulos, Patricia LoRusso, Deborah J.L. Wong, Siwen Hu-Lieskovan, Josefin-Beate Holz

A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers


Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1

Authors: Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Samuel Thomas, Eric D. Whitman, Omid Hamid, Jose Lutzky, Anna C. Pavlick, Jeffrey S. Weber, James M.G. Larkin, Debora Barton, Lotus Yung, Sam Suzuki, Maria Fardis, John M. Kirkwood

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors

Authors: Jason Alan Chesney, Jose Lutzky, Sajeve Samuel Thomas, Jorge J. Nieva, Eva Munoz Couselo, Juan Martin-Liberal, Juan Francisco Rodriguez-Moreno, Alex Cacovean, Huiling Li, Maria Fardis, Scott N. Gettinger

Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial

Authors: Julia Dianne Wulfkuhle, Christina Yau, Denise M. Wolf, Rosa Isela Gallagher, Lamorna Brown Swigart, Gillian L. Hirst, Michael Campbell, Rita Nanda, Minetta C. Liu, Lajos Pusztai, Laura Esserman, Donald A. Berry, Laura van ’t Veer, Emanuel Petricoin, I-SPY 2 Investigators
**Poster Session:**
**Saturday, June 1**
8:00 – 11:00 AM
**Location:** Hall A

**Developmental Therapeutics and Tumor Biology (Nonimmuno)**

*Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621*

**Authors:** Mark J. Ratain, Toshihiko Doi, Maja J. De Jonge, Patricia LoRusso, Martin Dunbar, Manoj Chiney, Monica Motwani, Jaimee Glasgow, Adam Matthew Petrich, Drew W. Rasco, Emiliano Calvo

*A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors*

**Authors:** Curtis Robert Chong, Todd Michael Bauer, Scott Andrew Laurie, Manish R. Patel, Noboru Yamamoto, Tiffany Davenport, Junxian Geng, Neil Gibson, Markus P. Vallaster, Patricia LoRusso

**Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network**

**Authors:** James V. Tricoli, Linda Zane, Robin Harrington, Laura Yee, Kneshay N. Harper, Ting-Chia Chang, Lyndsay Harris, Alice P. Chen, Keith Flaherty, Peter J. O’Dwyer, Barbara A. Conley, Cynthia Winter, Jennifer Lee, Paul M. Williams, Jeffrey Sklar, David Patton, Gregory J. Tsongalis, Stanley R. Hamilton, A. John Iafrate, Chris Alan Karlovich

**Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance)**

**Authors:** Brendan John Guercio, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael N. Pollak, Andrew B. Nixon, Michelle R. Mahoney, Bert O’Neil, James Edward Shaw, Blase N. Polite, Crystal S. Denlinger, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Charles David Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt

**SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors**

**Authors:** David S. Hong, Omid S. Tehrani, Howard Safran, Conor Ernst Steuer, Jill Lacy, Matthew H. Taylor, Thomas J. George, Reshma A. Rangwala, Shweta Jain, Leonardo Viana Nicacio, May Thet Cho

**TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy**

**Authors:** Scott T. Tagawa, Daniel Peter Petrylak, Petros Grivas, Neeraj Agarwal, Cora N. Sternberg, Chris Hernandez, Peggy Siemon-Hryczyk, Trishna Goswami, Yohann Loriot
**Poster Session:**
**Saturday, June 1**
8:00 – 11:00 AM
**Location:** Hall A

**Sarcoma**

*Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis*

**Author:** Mark A. Eckardt, Danielle S. Graham, Arun S. Singh, Bartosz Chmielowski, Noah Federman, Anusha Kalbasi, Nicholas M. Bernthal, Susan V. Bukata, Francis J. Hornicek, Jane Yanagawa, Benjamin D. Levine, Kambiz Motamedi, Leanne L. Seeger, Jeffrey J. Eckardt, Frederick R. Eilber, Sarah M. Dry, Scott D. Nelson, Frederick C. Eilber

*Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?*

**Authors:** Mudit Chowdhary, Akansha Chowdhary, Neilayan Sen, Nicholas George Zaorsky, Kirtesh R. Patel, Dian Wang

---

**Poster Session:**
**Saturday, June 1**
8:00 – 11:00 AM
**Location:** Hall A

**Pediatric Oncology**

*Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group*

**Authors:** Furqan Shaikh, Daniel P. Stark, Ha Dang, Caihong Xia, Mark D. Krailo, Sally Patricia Stenning, Farzana D. Pashankar, Carlos Rodriguez-Galindo, Thomas Arthur Olson, Juliet Hale, Sarita Depani, Sara Stoneham, James Nicholson, Matthew Murray, James F. Amatruda, Deborah F Billmire, Adriana Fonseca, A. Lindsay Frazier

*Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium*

**Authors:** Allison Frances O’Neill, Caihong Xia, Mark D. Krailo, Furqan Shaikh, Farzana D. Pashankar, Deborah F Billmire, Thomas Arthur Olson, James F. Amatruda, Doojduen Villaluna, Marcio H. Malogolowkin, Carlos Rodriguez-Galindo, A. Lindsay Frazier

---

**Poster Session:**
**Saturday, June 1**
1:15 – 4:15 PM
**Location:** Hall A

**Health Services Research, Clinical Informatics and Quality of Care**

*Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago*

**Authors:** Gerneiva Parkinson, Anees B. Chagpar, Kellie Alleyne-Mike, Marcella Nunez-Smith, Alicia Zhou, Lily Servais, Erin Wysong Hofstatter
Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer

Authors: Vikram Jairam, Daniel X. Yang, James B. Yu, Henry S. Park

Impact of an oncology urgent care clinic on emergency department rates

Authors: Tannaz Sedghi, Maureen Canavan, Cary Philip Gross, Amy J. Davidoff, Bonnie Elyssa Gould Rothberg, Michael Strait, Naralys Sinanis, Kerin B. Adelson

Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials

Authors: Guillermo de Velasco, David Lora, Alberto Carretero-Gonzalez, Maria Cruz Martin Soberón, Juan Manuel Manuel Sepulveda Sanchez, David Lorente, Daniel E. Castellano

Poster Session:
Saturday, June 1
1:15 – 4:15 PM
Location: Hall A

Head and Neck Cancer

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers


Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state

Authors: Kevin J. Harrington, Ezra E.W. Cohen, Denis Soulieres, José Dinis, Lisa F. Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal H. Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Jianxin Lin, Jonathan D. Cheng, Ramona F. Swaby, Christophe Le Tourneau

Poster Session:
Saturday, June 1
1:15 – 4:15 PM
Location: Hall A

Genitourinary (Prostate) Cancer

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC)

Authors: Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Yakovlevich Alekseev, Taro Iguchi, Neal D. Shore, Brad Rosbrook, Benoit Baron, Lucy F. Chen, Arnulf Stenzl

Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC)

Authors: Michael J. Morris, Jeremy C. Durack, Ajjai Shivaram Alva, Hebert Alberto Vargas, Morand Pier, Russell Kent Pachynski, Frederic Pouliot, Jean-Mathieu Beauregard, Mark A. Preston, Atish Dipankar Choudhury, Lawrence Saperstein, Peter Carroll, Steven P. Rowe, Kenneth J. Pienta, Tess Lin, Vivien Wong, Melissa Nichols, Jessica Donato Jensen, Barry A. Siegel

External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

Authors: Susan Halabi, Sandipan Dutta, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael Anthony Carducci, Kim N. Chi, Johann S. De Bono, Daniel Peter Petrylak, Karim Fizazi, Celestia S. Higano, Eric Jay Small, William Kevin Kelly

PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC)

Authors: Susan Halabi, Sandipan Dutta, Kim N. Chi, Catherine M. Tangen, Mengdi Xuan, Daniel Peter Petrylak, John C. Araujo, Karim Fizazi, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian Tannock, Eric Jay Small, William Kevin Kelly

A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR)

Authors: Michael J. Morris, Frederic Pouliot, Lawrence Saperstein, Steven P. Rowe, Michael A. Gorin, David Y. Josephson, Jeffrey Y.C. Wong, Peter Carroll, Tess Lin, Nancy Stambler, Vivien Wong, Jessica Donato Jensen, Barry A. Siegel

Poster Session:
Saturday, June 1
1:15 – 4:15 PM
Location: Hall A

Education Research and Professional Development
It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical oncology (SO) program leadership positions

Authors: Mudit Chowdhary, Akansha Chowdhary, Kirtesh R. Patel, Trevor J. Royce, Neilayan Sen, Parul Nafees Barry, Shikha Jain, Ruta D. Rao, Mia Alyce Levy, Miriam Knoll, Neha Vapiwala, Dian Wang, Barbara Pro, Gaurav Marwaha
Clinical Science Symposium:
Sunday, June 2
8:00 – 9:30 AM
Location: S406
Are We Hitting the Bull’s-eye With Targeted Therapy?
Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 Trial

Poster Session:
Sunday, June 2
8:00 – 11:00 AM
Location: Hall A
Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC
Authors: Ranjan Pathak, Jessica R Hoag, Sarah B. Goldberg, Andres F Monsalve, Benjamin Resio, Daniel J. Boffa
Benefit of combining local treatment and systemic therapy for Stave IV NSCLC: Results from the National Cancer Database
Authors: Meaghan Dendy Case, Johannes Uhlig, Justin Blasberg, Daniel J. Boffa, Anne C. Chiang, Scott N. Gettinger, Hyun S. Kim
Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer
Authors: Salma K. Jabbour, Abigail T. Berman, Roy H. Decker, Yong Lin, Steven J. Feigenberg, Scott N. Gettinger, Charu Aggarwal, Corey J. Langer, Charles B. Simone, Jeffrey D. Bradley, Joseph Aisner, Jyoti Malhotra
S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC)
**Poster Session:**
**Sunday, June 2**
8:00 – 11:00 AM

**Location:** Hall A

**Lung Cancer – Non-Small Cell Metastatic**

Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer

**Authors:** Michael Leapman, Carolyn J Presley, Weiwei Zhu, Pamela R. Soulos, Kerin B. Adelson, Daniel J. Boffa, Cary Philip Gross

*Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non-small-cell lung cancer (NSCLC): LEAP-006*

**Authors:** Rina Hui, Makoto Nishio, Martin Reck, Delvys Rodriguez-Abreu, Tamer M. Fouad, Doreen Flaim, Lina Yin, Thao Dang, Roy S. Herbst

*A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952)*

**Authors:** Lyudmila Bazhenova, Mary Weber Redman, Scott N. Gettinger, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, David R. Gandara, Jeffrey D. Bradley, Tom Stinchcombe, Natasha B. Leighl, Suresh S. Ramalingam, Susan S Tavernier, Katherine Minichiello, Karen Kelly, Vassiliki Papadimitrakopoulou, Roy S. Herbst

*Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001*

**Authors:** Edward B. Garon, Matthew David Hellmann, Enric Carcereny Costa, Natasha B. Leighl, Myung-Ju Ahn, Joseph Paul Eder, Ani Sarkis Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew A. Gubens, Suresh S. Ramalingam, Enriqueta Felip, Cathie Scalzo, Erin Jensen, Debra A. Kush, Rina Hui

*Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure*

**Authors:** Daniel Morgensztern, Rachel E. Sanborn, Lyudmila Bazhenova, Saiama Naheed Waqar, Lori McDermott, Jeff Hutchins, David L. Rimm, Luis E. Raez, Corey J. Langer, Roger B. Cohen

*Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753)*


*Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study*

**Authors:** Martin Gutierrez, Matthew David Hellmann, Matthew A. Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Wing Yan Chiu, Jong Seok Lee, James Chih-Hsin Yang, Edward B. Garon, Andrea Basso, Hua Ma, Lawrence Fong, Alex Snyder, Jianda Yuan, Roy S. Herbst
**Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC**


*A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G)*

**Authors:** Taofeek Kunle Owonikoko, Mary Weber Redman, Lauren Averett Byers, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, Jeffrey D. Bradley, Tom Stinchcombe, Natasha B. Leighl, Tareq Al Baghdadi, Primo Lara, Jieling Miao, Karen Kelly, Suresh S. Ramalingam, Roy S. Herbst, Vassiliki Papadimitrakopoulou, David R. Gandara

**Poster Session:**
**Sunday, June 2**
8:00 – 11:00 AM  
**Location:** Hall A

**Central Nervous System Tumors**

*Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases*

**Authors:** Benjamin Y. Lu, Richa Gupta, Tyler Stewart, Harriet M. Kluger, Lucia Jilaveanu, Kurt A. Schalper, Sarah B. Goldberg

**Poster Session:**
**Sunday, June 2**
8:00 – 11:00 AM  
**Location:** Hall A

**Breast Cancer – Local/Regional/Adjuvant**

*Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care*

**Authors:** Xiao Xu, Pamela R. Soullos, Jeph Herrin, Shi-Yi Wang, Craig Evan Pollack, Suzanne B. Evans, Cary Philip Gross, James B. Yu

*Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI*

**Authors:** Manasa Vulchi, Mohammed El Adoui, Nathaniel Braman, Paulette Turk, Maryam Etessami, Stylianos Drisis, Donna Plecha, Mohammed Benjelloun, Anant Madabhushi, Jame Abraham

*On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome*

**Authors:** Stephen James Luen, Gaia Griguolo, Paolo Nuciforo, Christine Campbell, Roberta Fasani, Javier Cortes, Michael Untch, Suling Joyce Lin, Peter Savas, Stephen B. Fox, Serena Di Cosimo, Antonio Llombart Cussac, Evandro de Azambuja, Martine J. Piccart-Gebhart, Lajos Pusztai, Christos Sotiriou, Roberto Salgado, Aleix Prat, Sherene Loi
Poster Session:
Sunday, June 2
8:00 – 11:00 AM
Location: Hall A

**Breast Cancer – Metastatic**

*Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2– advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results*

Authors: Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy Sanders Clark, Amelia Bruce Zelnak, Denise A. Yardley, Meghan Sri Karuturi, Tara B. Sanft, Sibel Blau, Lowell L. Hart, Cynthia X. Ma, Nicola Caria, D. Das Purkayastha, Alomi Mistry, Stacy L. Moulder

*Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA)*

Authors: Paul W. Sperduto, Shane Mesko, Daniel Cagney, Eric Nesbit, Jason Chan, Jessica Lee, Will Breen, Diana Shi, Hany Soliman, Ryan Shanley, Ashlyn S. Everett, Laura Masucci, Jill Remick, Kristin Plichta, Supriya K. Jain, Cheng-Chia Wu, John Bryant, James B. Yu, Toshimichi Nakano, Minesh P. Mehta

Oral Abstract Session
Sunday, June 2
8:00 – 11:00 AM
Location: S504

**Pediatric Oncology II**

*Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study*


Oral Abstract Session
Sunday, June 2
8:00 – 11:00 AM
Location: Hall D2

**Developmental Immunotherapy and Tumor Immunobiology**

*Phase I study of pembrolizumab in people with HIV and cancer*

Authors: Thomas S. Uldrick, Priscila Hermont Goncalves, Mohammad Maher Abdul Hay, Alisa J Claeyts, Brinda Emu, Marc S. Ernoff, Lawrence Fong, Judith C Kaiser, Holbrook Edwin Kohr, Andreeanne Lacroix, Steve Young Lee, Lisa Lundgren, Kathryn Anne Lurain, Christopher Parsons, Sharavi Peeramsetti, Ramya Ramaswami, Elad Sharon, Chia-Ching Jackie Wang, Robert Yarchoan, Martin A. Cheever
Oral Abstract Session:
Monday, June 3
9:45 AM – 12:45 PM
Location: E451

Hematologic Malignancies – Plasma Cell Dyscrasia
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma

Plenary Session:
Sunday, June 2
1:00 – 4:00 PM
Location: Hall B1

Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment
Authors: Blythe J.S. Adamson, Aaron B. Cohen, Melissa Estevez, Kelly Magee, Erin Williams, Cary Philip Gross, Neal J. Meropol, Amy J. Davidoff

Oral Abstract Session:
Sunday, June 2
9:45 AM – 12:45 PM
Location: Arie Crown Theater

Gastrointestinal (Noncolorectal) Cancer
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

Oral Abstract Session:
Monday, June 3
8:00 – 11:00 AM
Location: Arie Crown Theater

Genitourinary (Nonprostate) Cancer
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors
**Hematologic Malignancies – Plasma Cell Dyscrasia**

*Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents*

**Authors:** Smith Giri, Scott F. Huntington, Rong Wang, Amer Methqal Zeidan, Nikolai Alexandrovich Podoltsev, Steven Gore, Xiaomei Ma, Cary Philip Gross, Amy J. Davidoff, Natalia Neparidze

**Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia**

*Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy*

**Authors:** dReza Sirous, Ali Abbas Bukhari, Firas El Chaer, Jean Yared, Nancy Maureen Hardy, Mehmet Hakan Kocoglu, Ashraf Z. Badros, Azra Borogovac, Elizabeth Hutnick, Natalie Gahres, Kathleen Ruehle, Aaron Rapoport, Babak Saboury, Saurabh Dahiya

**Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allograft Transplant**

*Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia*

**Authors:** Olatoyosi Odenike, Johannes E. Wolff, Gautam Borthakur, Ibrahim Taha Aldoss, David Rizzieri, Thomas Prebet, Beibei Hu, Minh Dinh, Xiaotian Chen, Dimple Modi, Kevin J Freise, Brian Andrew Jonas

**Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)**

**Authors:** Courtney Denton Dinardo, Anthony Selwyn Stein, Eytan M. Stein, Amir Tahmasb Fathi, Olga Frankfurt, Andre C. Schuh, Giovanni Martinelli, Prapti Arvind Patel, Emmanuel Raffoux, Peter Tan, Amer Methqal Zeidan, Stéphane de Botton, Hagop M. Kantarjian, Richard M. Stone, Du Hung Lam, Jing Gong, Vickie Zhang, Thomas Winkler, Bin Wu, Paresh Vyas
Poster Session:
Monday, June 3
8:00 – 11:00 AM
Location: Hall A

**Gastrointestinal (Noncolorectal) Cancer**

*Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)*

**Authors:** Wungki Park, Winston Wong, Kenneth H. Yu, Anna M. Varghese, Nadeem Riaz, Vinod P. Balachandran, Imane H. El Dika, Nitya Prabhakar Raj, Danny Khalil, Geoffrey Yuyat Ku, Neil Howard Segal, Jia Li, Sree Bhavani Chalasani, Curtis Robert Chong, David Paul Kelsen, Ghassan K. Abou-Alfa, Michael F. Berger, Nikolaus Schultz, Christine A Iacobuzio-Donahue, Eileen Mary O’Reilly

*Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma*

**Authors:** Nitya Prabhakar Raj, Youyun Zheng, Virginia Kelly, Seth Katz, Joanne F Chou, Richard K. G. Do, Marinela Capanu, Dmitriy Zamarin, Charlotte Eielson Ariyan, Brian R. Untch, Eileen Mary O’Reilly, Anuradha Gopalan, Michael F. Berger, Kelly Olino, Neil Howard Segal, Diane Lauren Reidy

*Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059*


*KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase 3 study*

**Authors:** Yelena Yuriy Janjigian, Yung-Jue Bang, Charles S. Fuchs, Shukui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Z. Alexander Cao, Xinrun Chen, S. Peter Kang, Chie-Schin Shih, Hyun Cheol Chung

Oral Abstract Session:
Monday, June 3
8:00 – 11:00 AM
Location: E450

**Sarcoma**

*Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS)*

**Authors:** Neeta Somaiah, Brian Andrew Van Tine, Elizabeth Goodwin Hill, Mohammed M. Milhem, Scott Schuetze, Christian Frederick Meyer, Daniel Y. Reuben, Anthony D. Elias, William L. Read, Sant P. Chawla, Amy E. Wahlquist, Elizabeth Garrett-Mayer, Andrew S. Kra
Factors associated with breast cancer mortality-per-incident case in low-to-middle-income countries (LMICs)

Authors: Anees B. Chagpar, Mario Coccia

Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening

Authors: Daniel X. Yang, Danil V. Makarov, Cary Philip Gross, James B. Yu

Poster Session:
Monday, June 3
1:15 – 4:15 PM
Location: Hall A

Cancer Prevention, Hereditary Genetics and Epidemiology

Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma

Authors: Michael B. Atkins, John M. Kirkwood, Jedd D. Wolchok, Margaret K. Callahan, Harriet M. Kluger, Michael A. Postow, Neil Howard Segal, Alexander M. Lesokhin, Agnes Balogh, Sandra Re, Mario Sznol

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL)

Authors: Nikhil I. Khushalani, Adi Diab, Paolo Antonio Ascierto, James M.G. Larkin, Shahneen Kaur Sandhu, Mario Sznol, Henry B. Koon, Anthony Jarkowski, Ming Zhou, Rui Wang, Gaurav Bajaj, Georgina V. Long

Pharmacodynamic effect of IMCgp100 (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma

Authors: Mark R. Middleton, Neil Matthew Steven, TR Jeffry Evans, Jeffrey R. Infante, Omid Hamid, Alexander Noor Shoushtari, Philippa Gail Corrie, Alan Anthoney, Avinash Gupta, Victoria K Woodcock, Cheryl McAlpine, Mario Sznol

Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti-PD-1/PD-L1 agents: Phase 2 LEAP-004 study

Authors: ANA Maria Arance Fernandez, Paolo Antonio Ascierto, Matteo S. Carlino, Adil Daud, Alexander M. Eggermont, Axel Hauschild, Harriet M. Kluger, Matthew H. Taylor, Alan Smith, Ke Chen, Clemens Krepler, Scott J. Diede, Steven O’Day

Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma

Authors: Mark R. Middleton, Neil Matthew Steven, TR Jeffry Evans, Jeffrey R. Infante, Mario Sznol, Omid Hamid, Alexander Noor Shoushtari, Alan Anthoney, Avinash Gupta, Victoria K Woodcock, Rachael Easton, Philippa Gail Corrie

Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning

 Authors: Eric Robinson, Prathamesh M. Kulkarni, Jaya Sarin Pradhan, Robyn Denise Gartrell, Chen Yang, Emanuelle M. Rizk, Balazs Acs, Bethany Rohr, Robert Phelps, Tammie Ferringer, Basil Horst, David L. Rimm, Jing Wang, Yvonne M. Saenger
**Symptoms and Survivorship**

A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: *The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study*

**Authors:** Tara B. Sanft, Maura Harrigan, Brenda Cartmel, Leah M. Ferrucci, Karen Basen-Engquist, Dawn L. Hershman, Jennifer A. Ligibel, Marian Neuhouser, Anees B. Chagpar, Beth A. Jones, M. Tish Knobf, Andrea Silber, Fangyong Li, Melinda L. Irwin

**Identifying patient-reported anxiety and depression in older adults with cancer**

**Authors:** Reena Jayani, Can-Lan Sun, Kemeberly Charles, Enrique Soto Perez De Celis, Leana Chien, Elsa Roberts, Jeanine Moreno, William Dale, Supriya Gupta Mohile, Mina S. Sedrak, Marianna Koczywas, Vincent Chung, Marwan Fakih, Joseph Chao, Mihaela C. Cristea, Sumanta K. Pal, Vani Katheria, Arti Hurria, Daneng Li

**Genitourinary (Nonprostate) Cancer**

Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC)

**Authors:** Yohann Loriot, Arjun Vasant Balar, Robert Dreicer, Jean H. Hoffman-Censits, Jose Luis Perez-Gracia, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Xiaodong Shen, Qian (Cindy) Zhu, Beiying Ding, Constanze Kaiser, Jonathan E. Rosenberg

**EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer**

**Authors:** Christopher J. Hoimes, Jonathan E. Rosenberg, Daniel Peter Petrylak, Anne-Sophie Carret, Amal Melhem-Bertrandt, Thomas W. Flagg

**Infirgratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results**

**Authors:** Nazli Dizman, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, David I. Quinn, Daniel Peter Petrylak, Matt D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, Harris S. Soifer, Gary Li, Carl L. Dambkowski, Susan Moran, Yining Ye, Siamak Daneshmand, Dean F. Bajorin, Sumanta K. Pal

**Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC)**

**Authors:** Nieves Martinez Chanza, Wanling Xie, Majd Issa, Hannah Elizabeth Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Tat Lam, Yousef Zakharia, Rana R. McKay, Sumit Shah, Amir Mortazavi, Michael Roger Harrison, Toni K. Choueiri, Lauren Christine Harshman
**Oral Abstract Session:**
**Monday, June 3**
1:15 – 4:15 PM
**Location:** S406

**Gynecologic Cancer**
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial

**Authors:** Matthew A. Powell, Virginia L. Filiaci, Martee Leigh Hensley, Helen Q Huang, Kathleen N. Moore, Krishnansu Sujata Tewari, Larry J. Copeland, Angeles Alvarez Secord, David G Mutch, Alessandro Santin, William Richards, David Philip Warshal, Nicola M. Spirtos, Paul Disilverstro, Olga Ioffe, David S. Miller

**Oral Abstract Session:**
**Tuesday, June 4**
9:45 AM – 12:45 PM
**Location:** S406

**Melanoma/Skin Cancers**
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma

**Authors:** Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary Irvin Cohen, Omid Hamid, Laura Fulper Hutchins, Jeffrey Alan Sosman, Harriet M. Kluger, Vernon K. Sondak, Henry B. Koon, Donald P. Lawrence, Kari Lynn Kendra, David R. Minor, Carrie B. Lee, Mark R. Albertini, Lawrence E. Flaherty, Teresa M. Petrella, John M. Kirkwood
Central Nervous System Tumors
The impact of Epstein-Barr virus status on primary CNS lymphoma survival
Authors: Isabel P Prado, Frank Barbiero, Joachim M. Baehring, Kevin Becker, Zachary Corbin

Developmental Immunotherapy and Tumor Immunobiology
Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity
Authors: Michelle Ferreira, Irina Krykbaeva, William Damsky, Harriet M. Kluger, Marcus Bosenberg
Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC)
Authors: Tess O’Meara, Vesal Yaghoobi, Kim Blenman, Vasiliki Pelekanou, Andrea Silber, David L. Rimm, Lajos Pusztai

Developmental Therapeutics and Tumor Biology (Nonimmuno)
Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform
Authors: Ranjit Bindra, Ranjini K Sundaram, Robert J Aiello, Dan Marshall, Patricia Bourassa, Johanna Csengery, Qing Zhang, Brett Robinson, Lori Iopresti-Morrow, Jane Bechtold, Laurie Tylaska, Tim Paradis, Vishwas Paralkar, Per Hellsund, Peter Glazer

Gastrointestinal (Colorectal) Cancer
KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US
Authors: Johannes Uhlig, Stacey Stein, Jill Lacy, Hyun S. Kim

Gastrointestinal (Noncolorectal) Cancer
Meta-analysis of prognostic biomarkers for pancreatic neuroendocrine tumors (PNETs)
Authors: Mojun Zhu, Thorvardur Ragnar Halfdanarson, Bonnie Elyssa Gould Rothberg

Genitourinary (Nonprostate) Cancer
Stereotactic radiotherapy for stage I renal cell carcinoma: Overall survival and treatment trends compared to thermal ablation and surgical resection
Authors: Annemarie Uhlig, Johannes Uhlig, Lutz Trojan, Hyun S. Kim

Gynecologic Cancer
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
Authors: Burak Zeybek, Aranzazu Manzano, Anna Bianchi, Elena Bonazzoli, Natalia Buza, Salvatore Lopez, Emanuele Perrone, Paula Manara, Stefania Bellone, Luca Zammataro, Alessandro Santin
ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility
Authors: Oloruntoba Ismail Osagie, Zhigui Li, Shijun Mi, Jennifer T Aguilan, Gloria S. Huang

The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer
Authors: Wafa Khadraoui, Christina Tierney, Sophie Chung, Masoud Azodi, Elena Ratner, Gulden Menderes

Head and Neck Cancer
Translating transcriptome to immunophenotype in head and neck squamous cell carcinoma (HNSCC) to identify pathways promoting T-cell infiltration
Authors: Theodoros Rampias, Christos K. Kontos, Alexandros Polyzos, Aris Giotakis, Evangelos Giotakis, Andreas Scorilas, Euthymios Kirodimos, Periklis Foukas, Amanda Psyrri
Determining the biomarker landscape and its impact on outcomes in HPV+ head and neck cancer after primary resection
Authors: Suchin Rajeev Khanna, Trisha Michel Wise-Draper

Health Services Research, Clinical Informatics, and Quality of Care
Understanding cancer care coordination: Opening the black box
Authors: Maureen Canavan, Tannaz Sedghi, Cary Philip Gross, Stacey Lane, Jeanette Bogdan, Kerin B. Adelson
Are racial differences in obesity and insulin resistance related to aggressive breast cancer?
Authors: Emily Gallagher, Derek Leroith, Sheldon M. Feldman, Elisa R. Port, Neil B Friedman, Susan K Boolbol, Brigid K. Killelea, Lydia Choi, Kezhen Fei, Rebeca Franco, Radhi Yagnik, Daliz Cruz, Nina A. Bickell
Impact of dental insurance coverage on presentation, long-term outcomes, and symptom burden in locally advanced head and neck cancer
Authors: Alec Kacew, Ethan Harris, Glenn J. Hanna, Robert I. Haddad, Roy B. Tishler, Jonathan Daniel Schoenfeld, Danielle Nina Margalit, Alessandro Villa, Sewanti Atul Limaye, Matthew Sanborn, Ji Eun Bae, Umair Mahmood, Jennifer Cutler, Shana Criscitiello, Julian Huang, Ann H. Partridge, Jochen H. Lor
Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study
Authors: Natalia Sadetsky, Ching-Yi Chu, Amy J. Davidoff
The impact of race and socioeconomic status on outcomes for HPV-associated squamous cell carcinoma of the head and neck
Authors: Luke Roy George Pike, Trevor Joseph Royce, Amandeep R Mahal, Daniel W. Kim, William L. Hwang, Brandon Arvin Virgil Mahal, Nina Niu Sanford

Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Multicenter phase II trial of RRx-001 in previously treated SCLC
Authors: Daniel Morgensztern, Michal G. Rose, John Charles Morris, Patrick C. Ma, Christina E. Brzezniak, Karen Grace Zeman, Arvinda Padmanabhan, JoAnn Hirth, Alexander I. Spira, Ellice Yuen-Ming Wong, Sukhmani Kaur Padda, Saiama Naheed Waqar
Pediatric Oncology
Carcinomas in the children and young adults: A report form Children's Oncology Group APEC14B1 study
Authors: Rajkumar Venkatramani, Jin Piao, Mark D. Krailo, Carlos Rodriguez-Galindo, Farzana D. Pashankar

Symptoms and Survivorship
Cutaneous eruption as a prognosis indicator for cancer patients treated with EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis
Authors: Yensheng Wang, Jennifer Wu, Shi-Yi Wang, Mario E. Lacouture, Mei Wu, Wen-Hung Chung